Immutep LtdASX: IMM

Initiation of TACTI-004 phase 3 trial in 1st line NSCLC

· Issued by Immutep Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This pivotal trial will evaluate the combination of eftilagimod alfa with KEYTRUDA and chemotherapy against KEYTRUDA with chemotherapy and placebo. The receipt of regulatory approval from the Australian Therapeutic Goods Administration marks a significant milestone for the company.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

Story so far

Earlier from Immutep

Later from Immutep

All Immutep news releases